Daiichi Sankyo’s Financial Transformation
Revolutionizing enterprise budgeting through strategic optimization
Corporate Profile
Daiichi Sankyo Group is a global healthcare leader and the second-largest pharmaceutical company in Japan. Its regional headquarters, Daiichi Sankyo (China) Holdings Co., Ltd., was established in Shanghai in 2011 and orchestrates strategic investments and operational excellence across its subsidiaries in China.
With more than 1,500 employees nationwide and a state-of-the-art manufacturing facility in Shanghai, the organization drives innovation in oncology, cardiovascular care, and anti-infective therapies. As a pioneer in antibody-drug conjugate (ADC) therapeutics, Daiichi Sankyo’s global oncology pipeline includes breakthrough treatments for breast, gastric, and lung cancers. China is a pivotal growth market under its Vision 2030 ambition to become a “sustainable innovation-driven global healthcare leader.”
Challenges
1. Constantly Changing Budget Targets and Assumptions
Frequent policy shifts and market volatility necessitated multi-version, scenario-based budgeting, escalating the complexity and difficulty of financial planning.
2. Fragmented Data Ecosystems
Decentralized data standards across departments caused error-prone manual reconciliations, delaying critical decision timelines by 30–45 days each quarter.
3. Resource-Intensive Forecasting Cycles
Quarterly rolling forecasts consumed more than 500 person-hours monthly, diverting strategic focus from core R&D and commercialization priorities.
4. Analytical Infrastructure Gaps
Legacy systems lacked multi-dimensional reporting capabilities, requiring costly custom development to meet dual compliance standards for local GAAP and Japan headquarters.
5. Intercompany Settlement Bottlenecks
Manual allocation of more than $150 million in annual intra-group service charges hampered financial close processes and risked audit non-compliance across more than 20 entity-level reports.
Solution
Next-Generation Comprehensive Budgeting Platform
Partnering with EVOX, Daiichi Sankyo (China) implemented an enterprise-wide financial transformation solution featuring:
Agile Budgeting Framework
- Scenario-based modeling supporting more than 12 regulatory and competitive hypotheses
- Real-time KPI adjustments aligned with China’s dynamic healthcare policies
Unified Data Governance
- Centralized master data repository with ISO 8000-compliant standards
- Automated cross-departmental data validation workflows
Intelligent Forecasting Engine
- 70% reduction in quarterly rolling forecast cycles through AI-driven predictive analytics
- Dynamic resource allocation algorithms optimizing R&D OPEX efficiency
Advanced Analytics Platform
- Self-service multi-dimensional reporting across product, region, and therapeutic-area views
- Dual-compliance reporting templates reducing localization efforts by 40%
Automated Intercompany Reconciliation
- Automated settlement resolving 95% of intra-group disputes before close
- Unified P&L statements across entity, product, project, region, function, and other reporting dimensions
Quantifiable Business Impact
- 45% faster budget cycles, enabling rapid response to NMPA policy changes
- 99.2% data accuracy across financial statements through automated controls
- $2.1 million in annual savings from reduced manual reconciliation efforts
- 360° profitability insights, driving 15% portfolio optimization in oncology investments
- 30% faster month-end close, meeting both CSRC and J-GAAP requirements
A New Era of Financial Agility
This transformation establishes Daiichi Sankyo (China) as a benchmark for pharmaceutical financial innovation. By integrating predictive analytics, regulatory intelligence, and cross-border compliance automation, the organization now operates with:
- Real-time visibility into more than $800 million in regional OPEX
- Dynamic, risk-adjusted ROI modeling for more than 50 pipeline assets
- Collaborative workflows bridging Shanghai headquarters with 18 regional subsidiaries
As Daiichi Sankyo advances its mission to deliver “world-class healthcare solutions,” this strategic financial infrastructure positions the organization to lead China’s $140 billion oncology market while accelerating global ADC therapeutic breakthroughs.
Why Industry Leaders Choose EVOX
- Proven at Scale: More than 500 successful deployments across 20+ industries, including retail, manufacturing, pharmaceuticals, banking and finance, automotive, and services.
- Future-Proof Architecture: Cloud-agnostic deployment supports hybrid and multi-cloud environments and aligns with organizations’ evolving IT strategies.
- Investor-Validated Excellence: Backed by IDG Capital, Sequoia China, and other leading global investors, with more than $60 million in total funding—underscoring EVOX’s long-term commitment to innovation and customer success.
About EVOX
EVOX, owned by Espero Technology Pte. Ltd., is an AI-powered Enterprise Performance Management platform designed to connect data, business scenarios, and people—helping organizations evolve toward excellence. Featuring EVOX Budgeting & Planning, EVOX Consolidation, and EVOX SPM, the platform empowers enterprises to:
- Reduce monthly close cycles by more than 40%
- Elevate forecasting accuracy to confidence levels above 95%
- Achieve 100% audit-compliant financial consolidation
Headquartered in Singapore with worldwide business coverage, EVOX continues to redefine EPM for organizations.